pharma · Uveal Melanoma · HLA-A2 negative metastatic uveal melanoma · IDYA
IDEAYA Biosciences
IDEAYA Biosciences clinical programs — 5 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 5000 Shoreline Ct, Suite 300, South San Francisco, California 94080, US
- Founded
- 2015
- Employees
- 248
- Programs
- 14
- Drugs
- 12
- Patents
- 12
IDEAYA Biosciences projects
5 ClinicalTrials.gov programs sponsored by IDEAYA Biosciences.
IDEAYA Biosciences has 5 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
IDE-161
IDEAYA Biosciences
Advanced or Metastatic Solid Tumors
1 trial -
IDE034
IDEAYA Biosciences
Esophageal Squamous Cell Carcinoma
1 trial -
IDE397
IDEAYA Biosciences
Solid Tumor
1 trial -
IDE397-001
IDEAYA Biosciences
Advanced Solid Tumors
1 trial -
IDE892
IDEAYA Biosciences
NSCLC Adenocarcinoma
1 trial
Frequently asked questions
How many clinical projects does IDEAYA Biosciences have?
5 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.